Quantcast FDA Approvals FDA Approvals

​FDA Approvals

 

 

Targeting HER2-positive Breast Cancer4477The FDA has approved a new HER2-targeted therapeutic for the treatment of certain patients with early-stage breast cancer.7/24/2017 7:28:56 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1707042_HER2pos_Headshot_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting HER2-positive Breast CancerThe FDA has approved a new HER2-targeted therapeutic for the treatment of certain patients with early-stage breast cancer.46
Immunotherapeutic Use Expanded to Bladder Cancer909The FDA’s recent announcement means the immune checkpoint inhibitor pembrolizumab is now approved for five forms of cancer.6/21/2017 2:00:21 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1706008_Pembrolizumab_150x190_1.jpg" style="BORDER&#58;0px solid;" />Immunotherapeutic Use Expanded to Bladder CancerThe FDA’s recent announcement means the immune checkpoint inhibitor pembrolizumab is now approved for five forms of cancer.45
Targeting Tumors Based on a Biomarker3727The FDA’s new approval for the immunotherapeutic pembrolizumab is the first based entirely on a tumor biomarker rather than the site where the cancer originated.6/19/2017 8:32:38 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1706007_PembroBio_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting Tumors Based on a BiomarkerThe FDA’s new approval for the immunotherapeutic pembrolizumab is the first based entirely on a tumor biomarker rather than the site where the cancer originated.44
Another Immunotherapy Approved for Bladder Cancer3705Avelumab is the fourth immune checkpoint inhibitor to get FDA approval to treat certain patients with bladder cancer.6/19/2017 6:47:03 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1706010_Avelumab_150x190_1.jpg" style="BORDER&#58;0px solid;" />Another Immunotherapy Approved for Bladder CancerAvelumab is the fourth immune checkpoint inhibitor to get FDA approval to treat certain patients with bladder cancer. 43
A New Immunotherapy for Bladder Cancer809The FDA has approved a new immune checkpoint inhibitor, durvalumab, for the treatment of certain bladder cancer patients.6/14/2017 3:25:49 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1706009_durvalumab_150x190_1.jpg" style="BORDER&#58;0px solid;" />A New Immunotherapy for Bladder CancerThe FDA has approved a new immune checkpoint inhibitor, durvalumab, for the treatment of certain bladder cancer patients.42
Targeting Acute Myeloid Leukemia506A new molecularly targeted therapeutic for AML and other blood disorders has been approved by the FDA.6/12/2017 6:16:14 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1706011_Midostaurin_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting Acute Myeloid LeukemiaA new molecularly targeted therapeutic for AML and other blood disorders has been approved by the FDA.41
New Treatment for Liver Cancer Gets FDA Approval1263The approval expands the use of the anticancer therapeutic regorafenib (Stivarga) to a third cancer type. It is the first new treatment option for liver cancer in a decade.5/15/2017 8:08:19 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1705017_Therapeutic_150x190_1.jpg" style="BORDER&#58;0px solid;" />New Treatment for Liver Cancer Gets FDA ApprovalThe approval expands the use of the anticancer therapeutic regorafenib (Stivarga) to a third cancer type. It is the first new treatment option for liver cancer in a decade.40
Targeting Metastatic Lung Cancer1255The U.S. Food and Drug Administration adds a fourth molecularly targeted therapeutic option for the treatment of ALK-positive lung cancer.5/15/2017 7:26:43 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1705018_Lung_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting Metastatic Lung CancerThe U.S. Food and Drug Administration adds a fourth molecularly targeted therapeutic option for the treatment of ALK-positive lung cancer.39
New PARP Inhibitor Approved for Ovarian Cancer14211The U.S. Food and Drug Administration approval of niraparib means there are now three PARP inhibitors that can be used to treat women with ovarian cancer.4/26/2017 2:38:36 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1704018_Ovarian_150x190_2.jpg" style="BORDER&#58;0px solid;" />New PARP Inhibitor Approved for Ovarian CancerThe U.S. Food and Drug Administration approval of niraparib means there are now three PARP inhibitors that can be used to treat women with ovarian cancer.38
New Immuotherapeutic Approved for Rare Skin Cancer14210The U.S. Food and Drug Administration decision makes avelumab the first-ever approved treatment for metastatic Merkel cell carcinoma.4/26/2017 2:01:54 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1704019_MerkelCell_150x190_1a.jpg" style="BORDER&#58;0px solid;" />New Immuotherapeutic Approved for Rare Skin CancerThe U.S. Food and Drug Administration decision makes avelumab the first-ever approved treatment for metastatic Merkel cell carcinoma.37

The American Association for Cancer Research (AACR) is a 501c3 registered nonprofit organization with offices at 615 Chestnut Street, 17th Floor, Philadelphia, PA 19106 | 215.440.9300